The North American launch of a new range of mLLDPE resins will result in greater lightweighting, cost savings and sustainability for flexible packaging in the region, said manufacturers LyondellBasell.
Novasep’s API manufacturing facility in Le Mans, France has been certified under the potent compound safety programme run by occupational health and safety specialist SafeBridge Consultants.
News of Bayer’s selection of ex-Thermo Fisher Scientific boss Marijn Dekkers as its CEO was somewhat overshadowed by a new FDA warning letter about quality testing at its manufacturing facility in Bergkamen, Germany.
LyondellBasell is to close a low density polyethylene (LDPE) plant in the UK by the end of the year on continued weak demand and as it seeks to phase out uneconomic facilities from its global operations.
The global economic crisis has drastically reduced the growth of the North America API market, but brighter days are ahead according to new research by Global Markets Direct (GMD).
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
Chemicals firm Durect will supply drugmaker King Pharmaceuticals with two excipients used in the manufacture of the candidate anti-abuse painkiller Remoxy in an agreement signed last week.
Dainippon Sumitomo Pharma has entered into a collaboration to develop Silence Therapeutics’ AtuRNAi delivery technology which improves stability, cut manufacturing costs and increase stability.
The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important role, according to a new survey by industry analysts RNCOS.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
Perrigo’s API business posted a $5.4m (€3.8m) operating loss in Q4 because of restructuring charges but it believes vertically integrating production, and opening a site in India, will help in coming years.
Asahikasei’s chemicals unit has launched three new grades of pre-gelatinized starch excipients that it claims have broad application in the control of drug release, stability and disintegration.
PCAS is setting up a kilolab in California, US to target the small-scale synthesis market, which it believes will benefit its large-scale operations by establishing relationships earlier in development.
A dry powder measles vaccine formulation and inhalers that could be as affordable as needle treatments are due to enter Phase I in 2010, according to researchers at the ACS meeting.
Generic drugmaker Aurobindo Pharma will add liquid-injectables to its roster of manufacturing capabilities with the purchase of fellow Indian firm Trident Life Sciences (TLSL).
Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
US group Cambridge Major Laboratories (CML) will begin transferring API production to its 125,000 sq ft manufacturing plant in Germantown, Wisconsin at the end of next month.
SAFC Supply Solutions has launched a new materials sourcing offering, designed to meet the medical diagnostics sector’s demand for raw materials that are compliant with international regulatory standards.
Austria’s Borealis has brought its Bormed LE6609-PH BFS grade plastic back to market in a move that, it claims, will allow converters to speed up their production cycles by reducing autoclave residence time.
SAFC’s bioscience unit and Sartorius Stedim Biotech (SSB) have teamed up to create a suite of fluid management solutions that they hope will prove irresistible to the booming biomanufacturing sector.
BASF and Sinopec are to invest $1.4bn (€1bn) in expanding their Chinese specialty chemical joint venture, adding 10 plants and increasing capacity at three existing sites.
Ultrasonic particle engineering specialist Prosonix has been accredited under the ISO 9001:2008 quality scheme, after an inspection by the UK unit of independent auditing group SGS.
The USP is revising monographs of four pharmaceutical excipients in light of hazards associated with diethylene glycol contamination and is seeking comments from interested parties.
Dow Chemical is closing three US manufacturing plants, including an ethylene production unit in Hahnville, Louisiana in a further bid to restructure its specialty chemicals business.
US raw materials supplier Originates has boosted its pharmaceutical bovine hide gelatin manufacturing capacity with the addition of two new ISO 9000/9001 certified, GMP-standard production facilities in South America.
Rising demand in China has led to Toray Fine Chemicals (TFC) establishing a joint venture to produce dimethylsulfoxide (DMSO), a reaction solvent in pharma production.
US contractor Azopharma has added new GMP quality cytotoxics and high-potency manufacturing capacity at its facility in Hollywood, South Florida in a bid to strengthen its position in the trial materials sector.
Swiss drugmaker Helsinn has unveiled plans to add high-potency API R&D and manufacturing capacity to its facility in Biasca in the south of the country.
Sanofi-Aventis is using SCM Pharma’s aseptic fill/finish service for radiolabelled compounds to manufacture an oncology product that is in clinical trials.
Sweden’s Alfa Laval says ART PR49, its combined chemical reactor and heat transfer plate, improves the efficiency of chemical production and helps reduce energy costs.
Swedish CRO Syntagon has set up an office in Shanghai, China to forge stronger links with a broader range of local raw materials suppliers, saving its customers time and money.
Ireland’s API manufacturing sector suffered a blow on Friday with Corden Pharmachem’s announcement that it is phasing-out manufacturing at its facility in Little Island, Cork.
SAFC is seeking to improve its large-scale supply of pharma raw materials through a partnership with Cherokee Pharmaceuticals, which will use its expertise to ensure the products meet cGMP standards.
Sanofi Pasteur, the vaccines unit of French drug major Sanofi Aventis, has received a reference strain of the H1N1 swine flu virus from the US CDC and expects to complete work on an industrial “seed stock” in the next two weeks.
Wacker has brought its expanded cyclodextrin facility online following its $21m (€15m) expansion, which has significantly increased capacity in response to growing demand for the excipient.
Stiffer penalties for counterfeiters could be counterproductive in less developed countries (LDC) and “entrench the corrupt symbiotic relationship between counterfeiters, lawmakers and officials”, according to a report
Fine chemicals firm Minakem believes that manufacturing capacity added by its newly acquired API plant in Dunkirk, France will reduce costs and help it compete on a global scale.
Freeman Technologies, which showcased its FT4 Rheometer at Achema in Frankfurt, Germany, last week, says pharmaceutical powders are complex systems that require analysis of multiple parameters.
A new $60m (€43m) manufacturing suite is operational at the South Carolina, US plant where Roche makes APIs for some of its leading products, including for its anti-flu drug Tamiflu (oseltamivir).
German industrial phosphate maker Budenheim has been certified to produce calcium phosphates as pharmaceutical excipients under ICH Q7A GMP guidelines.
Two recombinant human albumins made by Novozymes' biopharma division have become the first to comply with the USP-NF's recently revised excipient monograph.
Novozymes Biopharma is building a new Bacillus-based hyaluronic acid (bHA) production facility in China to meet “increasing demand” for the substance that has drug delivery applications.
API maker Hovione’s manufacturing facility in Cork, Ireland was unveiled at an opening ceremony yesterday just two weeks after the previous owner, global drug giant Pfizer, formally handed over the keys.
Tom Beil, SAFC’s VP of Quality and Regulatory affairs, whose talk on fine chemicals supply was a highlight of last month's DCAT week, spoke with in-PharmaTechnologist about the benefits and risks of working with global suppliers.
Researchers have used plants from the tobacco family as a large-scale, cost-effective method of producing a HIV inhibitor, which could lead to the creation of a female controlled intervention to stop viral transmission.
